Moderna is trading at $212.16, down 10.29%, amid an active biotech-sector selloff.
- XBI was down 2.06% during the regular session.
- Citi’s recent Sell downgrade cited valuation concerns around potential cancer-vaccine sales, but reporting linked it to an earlier move, not specifically today’s decline.
- No verified new Moderna announcement on October 16 clearly explains the move; modestly mixed broad-market conditions do not establish a market-wide cause.